UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2018-09, Vol.16 (9), p.1891-1894

2018

Link zum Volltext

Verfügbarkeit prüfen

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2119-2126

2015

Link zum Volltext

Verfügbarkeit prüfen

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2019-10, Vol.17 (10), p.1772-1778

2019

Link zum Volltext

Verfügbarkeit prüfen

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Journal of thrombosis and haemostasis, 2015-12, Vol.13 (12), p.2187-2191

2015

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Journal of thrombosis and haemostasis, 2020-07, Vol.18 (7), p.1637-1647

2020

Link zum Volltext

Verfügbarkeit prüfen

Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2012-2020

2015

Link zum Volltext

Verfügbarkeit prüfen

Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study

Journal of thrombosis and haemostasis, 2017-10, Vol.15 (10), p.2017-2028

2017

Link zum Volltext

Verfügbarkeit prüfen

Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Journal of thrombosis and haemostasis, 2024-06, Vol.22 (6), p.1704-1714

2024

Link zum Volltext

Verfügbarkeit prüfen

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

Journal of thrombosis and haemostasis, 2018-01, Vol.16 (1), p.54-64

2018

Link zum Volltext

Verfügbarkeit prüfen

Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

Journal of thrombosis and haemostasis, 2016-11, Vol.14 (11), p.2194-2201

2016

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

Journal of thrombosis and haemostasis, 2020-10, Vol.18 (10), p.2532-2541

2020

Link zum Volltext

Verfügbarkeit prüfen

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism

Journal of thrombosis and haemostasis, 2018-09, Vol.16 (9), p.1775-1778

2018

Link zum Volltext

Verfügbarkeit prüfen

Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation

Journal of thrombosis and haemostasis, 2023-05, Vol.21 (5), p.1381-1384

2023

Link zum Volltext

Verfügbarkeit prüfen

Thrombin in complex with dabigatran can still interact with PAR‐1 via exosite‐I and instigate loss of vascular integrity

Journal of thrombosis and haemostasis, 2022-04, Vol.20 (4), p.996-1007

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease

Journal of thrombosis and haemostasis, 2023-06, Vol.21 (6), p.1601-1609

2023

Link zum Volltext

Verfügbarkeit prüfen

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

Journal of thrombosis and haemostasis, 2021-12, Vol.19 (12), p.3008-3017

2021

Link zum Volltext

Verfügbarkeit prüfen

Low‐dose apixaban in extended treatment of cancer‐associated thrombosis: Less is more?

Journal of thrombosis and haemostasis, 2022-05, Vol.20 (5), p.1070-1072

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists

Journal of thrombosis and haemostasis, 2015-09, Vol.13 (9), p.1590-1596

2015

Link zum Volltext

Verfügbarkeit prüfen

Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (S1), p.S187-S194

Dzik, W. H.

2015

Link zum Volltext

Verfügbarkeit prüfen

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome

Journal of thrombosis and haemostasis, 2015-07, Vol.13 (7), p.1264-1273

2015

Link zum Volltext

Verfügbarkeit prüfen

Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease

Journal of thrombosis and haemostasis, 2017-05, Vol.15 (5), p.925-930

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical uncertainty for the use of rivaroxaban in obesity

Journal of thrombosis and haemostasis, 2021-03, Vol.19 (3), p.870-871

2021

Link zum Volltext

Verfügbarkeit prüfen

Bleeding TAPs out

Journal of thrombosis and haemostasis, 2019-02, Vol.17 (2), p.247-249

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai‐VTE trial

Journal of thrombosis and haemostasis, 2015-09, Vol.13 (9), p.1606-1614

2015

Link zum Volltext

Verfügbarkeit prüfen

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

Journal of thrombosis and haemostasis, 2015-08, Vol.13 (8), p.1405-1413

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 65

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Thrombosis And Haemostasis

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(65)

Sprache

Englisch
(65)
Japanisch
(18)

Erscheinungsjahr

n.n

Thema

Humans
(64)
Cardiovascular System & Cardiology
(63)
Hematology
(63)
Life Sciences & Biomedicine
(63)
Peripheral Vascular Disease
(63)
Science & Technology
(63)
Factor Xa Inhibitors
(34)
Anticoagulants - Adverse Effects
(31)
Male
(30)
Female
(29)
Treatment Outcome
(28)
Hemorrhage - Chemically Induced
(27)
Middle Aged
(27)
Administration, Oral
(26)
Factor Xa Inhibitors - Adverse Effects
(26)
Aged
(25)
Anticoagulants
(24)
Adult
(20)
Anticoagulants - Administration & Dosage
(20)
Anticoagulants - Therapeutic Use
(17)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Thrombosis And Haemostasis : Jth
(1)

Menü

Weitere Dienste

Einstellungen

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials

Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study

Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa

Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism

Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation

Thrombin in complex with dabigatran can still interact with PAR‐1 via exosite‐I and instigate loss of vascular integrity

Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

Low‐dose apixaban in extended treatment of cancer‐associated thrombosis: Less is more?

Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists

Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re‐appraisal

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome

Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease

Clinical uncertainty for the use of rivaroxaban in obesity

Bleeding TAPs out

Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai‐VTE trial

A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

Aktive Filter

Suchergebnisse filtern